Erica De Vita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Erica De Vita has a total of 234 co-authors. Here are the top co-authors by number of shared publications:
Lara Tavoschi
Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa (PI), Italy
6 shared publications- Lara Tavoschi
Department of Translational Research and New Technologies in Medicine and Surgery University of Pisa Pisa Italy
4 shared publications Davide Petri
Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa, Pisa
3 shared publications- Guglielmo Arzilli
Department of Translational Research and New Technologies in Medicine and Surgery University of Pisa Pisa Italy
3 shared publications Maria Paola Tramonti Fantozzi
Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa (PI), Italy
3 shared publicationsAndrea Davide Porretta
Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
2 shared publications
Latest Publications
- Open Access
Knowledge, Attitudes, and Perceptions of HPV Vaccination for Adolescents with Intellectual Disabilities: A Systematic Review
Background/Objectives: Adolescents with intellectual disabilities may experience inequities in preventive healthcare, including HPV vaccination. This review aimed to synthesize evidence on HPV vaccination-related knowledge, attitudes and perceptions among adolescents with intellectual disabilities, parents/caregivers, educators, healthcare professionals and other stakeholders. Methods: A systematic search was conducted in PubMed, Embase and Scopus on 29 October 2025. Eligible studies reported original data on knowledge, attitudes or perceptions regarding HPV vaccination for adolescents with intellectual disabilities or relevant stakeholders. The protocol was registered on PROSPERO (CRD420251015183). Quantitative, qualitative and mixed-methods studies were considered. Results: Seven studies were included. They were conducted in the USA, Australia and the UK and involved parents/caregivers, healthcare providers, school staff, immunization staff and adolescents or young people with disabilities. Direct evidence from adolescents was limited. HPV-related knowledge was often limited or uneven, and standard information materials were perceived as insufficiently accessible. Parents/caregivers were often broadly supportive of vaccination, but HPV-specific acceptance was affected by perceived low susceptibility, assumptions about sexual inactivity, safety concerns, procedure-related distress and lack of provider recommendation. Healthcare providers generally supported HPV vaccination; however, recommendations were sometimes influenced by perceived sexual activity, age or consent. School-based vaccination was considered useful but required tailored information, preparation, individual adjustments and follow-up. Conclusions: Evidence on HPV vaccination-related knowledge, attitudes and perceptions among adolescents with intellectual disabilities and their stakeholders remains limited and geographically restricted. Improving equitable access may require interventions that should be further investigated, such as accessible communication, systematic provider recommendation, flexible vaccination pathways and greater involvement of adolescents in decision-making.
Open AccessKnowledge, Attitudes, and Perceptions of HPV Vaccination for Adolescents with Intellectual Disabilities: A Systematic Review
Background/Objectives: Adolescents with intellectual disabilities may experience inequities in preventive healthcare, including HPV vaccination. This review aimed to synthesize evidence on HPV vaccination-related knowledge, attitudes and perceptions among adolescents with intellectual disabilities, parents/caregivers, educators, healthcare professionals and other stakeholders. Methods: A systematic search was conducted in PubMed, Embase and Scopus on 29 October 2025. Eligible studies reported original data on knowledge, attitudes or perceptions regarding HPV vaccination for adolescents with intellectual disabilities or relevant stakeholders. The protocol was registered on PROSPERO (CRD420251015183). Quantitative, qualitative and mixed-methods studies were considered. Results: Seven studies were included. They were conducted in the USA, Australia and the UK and involved parents/caregivers, healthcare providers, school staff, immunization staff and adolescents or young people with disabilities. Direct evidence from adolescents was limited. HPV-related knowledge was often limited or uneven, and standard information materials were perceived as insufficiently accessible. Parents/caregivers were often broadly supportive of vaccination, but HPV-specific acceptance was affected by perceived low susceptibility, assumptions about sexual inactivity, safety concerns, procedure-related distress and lack of provider recommendation. Healthcare providers generally supported HPV vaccination; however, recommendations were sometimes influenced by perceived sexual activity, age or consent. School-based vaccination was considered useful but required tailored information, preparation, individual adjustments and follow-up. Conclusions: Evidence on HPV vaccination-related knowledge, attitudes and perceptions among adolescents with intellectual disabilities and their stakeholders remains limited and geographically restricted. Improving equitable access may require interventions that should be further investigated, such as accessible communication, systematic provider recommendation, flexible vaccination pathways and greater involvement of adolescents in decision-making.
- Open Access
Scaling up vaccination for people living in prisons: a global person-centred need for public health
- Open Access
- 25 June 2026
- Published by Springer Nature in BMC Public Health
- Vol. 26 (1)
Mapping risk communication practices in public health emergencies: a scoping review and comparison with Italian regional pandemic plans
Effective risk communication is a cornerstone of public health emergency preparedness and response. The COVID-19 pandemic and other recent crises have high
- 25 June 2026
- Published by Springer Nature in BMC Public Health
- Vol. 26 (1)
Open AccessMapping risk communication practices in public health emergencies: a scoping review and comparison with Italian regional pandemic plans
Effective risk communication is a cornerstone of public health emergency preparedness and response. The COVID-19 pandemic and other recent crises have high
- Open Access
- 11 March 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (3) , e0343936
Clinical outcomes and patient-reported measures in HCV care: Insight from a longitudinal prospective study in a large Italian region
Background: Hepatitis C virus (HCV) infection remains a critical public health issue worldwide. Direct-acting antivirals (DAAs) have revolutionized the treatment of hepatitis C. However, real-world elimination efforts are hindered by barriers in diagnosis, treatment access, and follow-up. Embedding patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) into routine care may improve service delivery. This study evaluates clinical and patient-reported outcomes in the HCV care cascade in Tuscany (Italy), offering insights into how health service organization affects effectiveness, equity, and patient experience. Methods: We conducted a multicenter, longitudinal, prospective study on 953 adults with HCV chronic infection. These adults were treated between 2021 and 2023 in seven prescribing centers in Tuscany. Clinical data included demographics, comorbidities, fibrosis staging, virological response (SVR12), and loss to follow-up (LTFU). PROMs and PREMs were collected at baseline (T0), 3 months post-treatment (T1), and 6 months after T1 (T2). We used the SF-12 tool and custom surveys. Patients were stratified by referral source (GPs, harm reduction services/prison, specialists). Clinical and questionnaire data were analyzed separately. Statistical analyses included ANOVA, Chi-square, Kruskal-Wallis, Cochran’s Q, Friedman, and repeated measures ANOVA with Bonferroni corrections. Significance was set at p ≤ 0.05. Results: DAA therapy achieved high clinical efficacy: SVR12 was reached in 93.4% of patients. The rate rose to 98.6% when excluding those lost to follow-up. Patients referred by harm reduction/prison services were younger and mostly male. They had higher psychiatric comorbidities and risk behaviors. PROMs demonstrated significant improvements in perceived physical and emotional health following treatment, particularly among individuals referred by GPs and specialists. PREMs revealed increasing satisfaction with referring doctors over time. Satisfaction with specialist care remained high and stable. Referral pathways markedly influenced patient profiles and reported outcomes. There were notable disparities in experience and quality-of-life indicators. Conclusions: This study highlights the importance of integrating clinical and patient-reported data in monitoring HCV care. High SVR rates confirm the effectiveness of DAAs, while PROMs and PREMs provide valuable insight into patient engagement and equity of access. Stratified analyses reveal the need for tailored approaches across care pathways, and high-risk populations require special attention. Embedding patient voice in evaluation fosters a more responsive, people-centered health system, advancing progress toward HCV elimination.
- 11 March 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (3) , e0343936
Open AccessClinical outcomes and patient-reported measures in HCV care: Insight from a longitudinal prospective study in a large Italian region
Background: Hepatitis C virus (HCV) infection remains a critical public health issue worldwide. Direct-acting antivirals (DAAs) have revolutionized the treatment of hepatitis C. However, real-world elimination efforts are hindered by barriers in diagnosis, treatment access, and follow-up. Embedding patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) into routine care may improve service delivery. This study evaluates clinical and patient-reported outcomes in the HCV care cascade in Tuscany (Italy), offering insights into how health service organization affects effectiveness, equity, and patient experience. Methods: We conducted a multicenter, longitudinal, prospective study on 953 adults with HCV chronic infection. These adults were treated between 2021 and 2023 in seven prescribing centers in Tuscany. Clinical data included demographics, comorbidities, fibrosis staging, virological response (SVR12), and loss to follow-up (LTFU). PROMs and PREMs were collected at baseline (T0), 3 months post-treatment (T1), and 6 months after T1 (T2). We used the SF-12 tool and custom surveys. Patients were stratified by referral source (GPs, harm reduction services/prison, specialists). Clinical and questionnaire data were analyzed separately. Statistical analyses included ANOVA, Chi-square, Kruskal-Wallis, Cochran’s Q, Friedman, and repeated measures ANOVA with Bonferroni corrections. Significance was set at p ≤ 0.05. Results: DAA therapy achieved high clinical efficacy: SVR12 was reached in 93.4% of patients. The rate rose to 98.6% when excluding those lost to follow-up. Patients referred by harm reduction/prison services were younger and mostly male. They had higher psychiatric comorbidities and risk behaviors. PROMs demonstrated significant improvements in perceived physical and emotional health following treatment, particularly among individuals referred by GPs and specialists. PREMs revealed increasing satisfaction with referring doctors over time. Satisfaction with specialist care remained high and stable. Referral pathways markedly influenced patient profiles and reported outcomes. There were notable disparities in experience and quality-of-life indicators. Conclusions: This study highlights the importance of integrating clinical and patient-reported data in monitoring HCV care. High SVR rates confirm the effectiveness of DAAs, while PROMs and PREMs provide valuable insight into patient engagement and equity of access. Stratified analyses reveal the need for tailored approaches across care pathways, and high-risk populations require special attention. Embedding patient voice in evaluation fosters a more responsive, people-centered health system, advancing progress toward HCV elimination.
- Open Access
- 5 December 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (12) , 2773
Integrating Statistical and Machine-Learning Approaches for Salmonella enterica Surveillance in Northwestern Italy: A One Health Data-Driven Framework
Salmonella enterica is a major cause of foodborne illness globally. We analysed 41,945 food samples collected under official surveillance in Piedmont (north-western Italy) between 2013 and 2023 to characterise contamination patterns and evaluate an integrated analytical framework combining classical statistical modelling with machine-learning prediction. Overall prevalence was low (2.20%; 95% CI: 2.06–2.35) but heterogeneous across matrices, with poultry and pork displaying the highest contamination levels (11.8% and 7.14%). Risk increased at distribution/retail stages, and contamination declined markedly from 2013 to 2018, with lower levels in late autumn. Meteorological factors had minimal influence. Mixed-effects models identified food category and production stage as the main determinants of contamination, while the XGBoost algorithm showed stable predictive performance (median absolute error ≈ 0.02) and spatially coherent estimates. SHAP analyses confirmed food composition variables as the dominant predictors. These findings highlight persistent vulnerabilities within poultry and swine supply chains, particularly at post-production stages, and illustrate the complementary value of combining explanatory and predictive approaches to strengthen risk-based, One Health-aligned food-safety surveillance.
- 5 December 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (12) , 2773
Open AccessIntegrating Statistical and Machine-Learning Approaches for Salmonella enterica Surveillance in Northwestern Italy: A One Health Data-Driven Framework
Salmonella enterica is a major cause of foodborne illness globally. We analysed 41,945 food samples collected under official surveillance in Piedmont (north-western Italy) between 2013 and 2023 to characterise contamination patterns and evaluate an integrated analytical framework combining classical statistical modelling with machine-learning prediction. Overall prevalence was low (2.20%; 95% CI: 2.06–2.35) but heterogeneous across matrices, with poultry and pork displaying the highest contamination levels (11.8% and 7.14%). Risk increased at distribution/retail stages, and contamination declined markedly from 2013 to 2018, with lower levels in late autumn. Meteorological factors had minimal influence. Mixed-effects models identified food category and production stage as the main determinants of contamination, while the XGBoost algorithm showed stable predictive performance (median absolute error ≈ 0.02) and spatially coherent estimates. SHAP analyses confirmed food composition variables as the dominant predictors. These findings highlight persistent vulnerabilities within poultry and swine supply chains, particularly at post-production stages, and illustrate the complementary value of combining explanatory and predictive approaches to strengthen risk-based, One Health-aligned food-safety surveillance.
- Open Access
- 21 November 2025
- Published by Elsevier in The Lancet Primary Care
- Vol. 1 (6)
Why are Europe’s underserved still unprotected? A call to address structural barriers to immunisation
- 21 November 2025
- Published by Elsevier in The Lancet Primary Care
- Vol. 1 (6)
Open AccessWhy are Europe’s underserved still unprotected? A call to address structural barriers to immunisation
- Open Access
- 8 October 2025
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 21 (1) , 2569734
Social media insights on the introduction of RSV immunoprophylaxis in Italy
The introduction of new immunoprophylaxis strategies against respiratory syncytial virus (RSV), such as maternal vaccination and the administration of monoclonal antibodies to newborns, presents both opportunities and challenges in terms of public understanding and acceptance. Monitoring online discussions can offer timely insights into perceptions of these interventions. We conducted a social media monitoring activity in Italy from September 2024 to January 2025, using the Pulsar platform to analyze posts on X and Facebook, complemented by manual analysis of comments on Instagram and TikTok. We examined content related to RSV prevention, focusing on stance, recurring narratives, and specific questions or doubts. Most content showed a neutral or supportive stance toward RSV immunoprophylaxis, with many users expressing awareness of RSV risk and interest in accessing the monoclonal antibody. However, recurring information needs emerged around eligibility, access, safety, and the distinction between different prevention options. Criticism toward the government was also observed, linked to initial decisions that limited free provision of the antibody to certain regions, later reversed, which left perceptions of inequality. Only a limited proportion of posts contained clear misinformation or disinformation. These results were consistent with recent surveys in other countries showing high parental acceptance of similar interventions. These findings underscore the need to address specific information gaps and ensure clear, consistent communication to support trust in RSV immunoprophylaxis. Proactive efforts will be important to reinforce the generally positive attitudes observed and to mitigate concerns that could affect the acceptance of new preventive measures.
- 8 October 2025
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 21 (1) , 2569734
Open AccessSocial media insights on the introduction of RSV immunoprophylaxis in Italy
The introduction of new immunoprophylaxis strategies against respiratory syncytial virus (RSV), such as maternal vaccination and the administration of monoclonal antibodies to newborns, presents both opportunities and challenges in terms of public understanding and acceptance. Monitoring online discussions can offer timely insights into perceptions of these interventions. We conducted a social media monitoring activity in Italy from September 2024 to January 2025, using the Pulsar platform to analyze posts on X and Facebook, complemented by manual analysis of comments on Instagram and TikTok. We examined content related to RSV prevention, focusing on stance, recurring narratives, and specific questions or doubts. Most content showed a neutral or supportive stance toward RSV immunoprophylaxis, with many users expressing awareness of RSV risk and interest in accessing the monoclonal antibody. However, recurring information needs emerged around eligibility, access, safety, and the distinction between different prevention options. Criticism toward the government was also observed, linked to initial decisions that limited free provision of the antibody to certain regions, later reversed, which left perceptions of inequality. Only a limited proportion of posts contained clear misinformation or disinformation. These results were consistent with recent surveys in other countries showing high parental acceptance of similar interventions. These findings underscore the need to address specific information gaps and ensure clear, consistent communication to support trust in RSV immunoprophylaxis. Proactive efforts will be important to reinforce the generally positive attitudes observed and to mitigate concerns that could affect the acceptance of new preventive measures.
- 1 January 2025
- Vol. 49 (2-3) , 151-152
[Strengthen and expand vaccination provision in prisons to promote access to preventive tools and health equity].
- 1 January 2025
- Vol. 49 (2-3) , 151-152
[Strengthen and expand vaccination provision in prisons to promote access to preventive tools and health equity].
- Open Access
- 28 October 2024
- Published by Oxford University Press (OUP) in European Journal of Public Health
- Vol. 34 (Supplement)
Epidemiology of hepatitis C from 2015 to 2022 in a central Italian region: the OPT-HepaC project
Background: Chronic hepatitis C virus (HCV) infection is a major global public health problem. This study investigated the evolving landscape of HCV in Tuscany (Italy) from 2015 to 2022, considering demographic shifts, clinical profiles, treatment regimens, and outcomes. Methods: The study was conducted in order to characterize HCV-positive patients who started treatment between 2015 and 2022 in Tuscan prescribing centers. The study was part of OPT-HepaC, a project funded by Regional Health Service. Data on demographics, clinical history and outcomes were collected. Three different temporal eras were analysed: the period before andfter the universal availability of direct-acting antivirals (DAA) and the COVID-19 era. Treatment’s effectiveness was evaluated by the Sustained Virological Response (SVR12), assessed 12 weeks after the end of treatment. Outcomes included SVR12, non-SVR12 and lost to follow-up (LTFU). ANOVA, Kruskal-Wallis test and multinomial logistic regression were used for statistical analysis. Results: 6882 HCV patients (age: 58.88±14.21) were treated by the centres participating at the study. Males (56.4%) and Italian (91.8%) were predominant. Sociodemographic and variable characteristics vary across the time. While the overall SVR12 remained stable over time (χ2(2)=0.357, p = 0.837), the LTFU rate significantly increased during the COVID-19 era. Facilitating factors for the non-SVR12 and LTFU outcomes were male gender (Odds Ratio (OR)=2.134, p = 0.006)/cirrhosis (OR = 1.713, p = 0.040)/HIV co-infection (OR = 3.251, p = 0.005) and DAA treatment of third generation (OR = 4.187, p = 0.006), respectively. Conclusions: The study provides a comprehensive view of the HCV landscape, highlighting demographic changes, treatment regimens and outcomes. The COVID-19 pandemic affected service delivery, delaying HCV diagnosis/treatment and influencing the LTFU rate. Despite challenges, the region maintained high SVR12 rates, emphasizing the importance of sustained efforts in HCV care. Key messages: • The study highlights the dynamic nature of HCV management in Tuscany. • The study emphasises the need for continuous adaptation to public health challenges, providing insights for future public health strategies.
- 28 October 2024
- Published by Oxford University Press (OUP) in European Journal of Public Health
- Vol. 34 (Supplement)
Open AccessEpidemiology of hepatitis C from 2015 to 2022 in a central Italian region: the OPT-HepaC project
Background: Chronic hepatitis C virus (HCV) infection is a major global public health problem. This study investigated the evolving landscape of HCV in Tuscany (Italy) from 2015 to 2022, considering demographic shifts, clinical profiles, treatment regimens, and outcomes. Methods: The study was conducted in order to characterize HCV-positive patients who started treatment between 2015 and 2022 in Tuscan prescribing centers. The study was part of OPT-HepaC, a project funded by Regional Health Service. Data on demographics, clinical history and outcomes were collected. Three different temporal eras were analysed: the period before andfter the universal availability of direct-acting antivirals (DAA) and the COVID-19 era. Treatment’s effectiveness was evaluated by the Sustained Virological Response (SVR12), assessed 12 weeks after the end of treatment. Outcomes included SVR12, non-SVR12 and lost to follow-up (LTFU). ANOVA, Kruskal-Wallis test and multinomial logistic regression were used for statistical analysis. Results: 6882 HCV patients (age: 58.88±14.21) were treated by the centres participating at the study. Males (56.4%) and Italian (91.8%) were predominant. Sociodemographic and variable characteristics vary across the time. While the overall SVR12 remained stable over time (χ2(2)=0.357, p = 0.837), the LTFU rate significantly increased during the COVID-19 era. Facilitating factors for the non-SVR12 and LTFU outcomes were male gender (Odds Ratio (OR)=2.134, p = 0.006)/cirrhosis (OR = 1.713, p = 0.040)/HIV co-infection (OR = 3.251, p = 0.005) and DAA treatment of third generation (OR = 4.187, p = 0.006), respectively. Conclusions: The study provides a comprehensive view of the HCV landscape, highlighting demographic changes, treatment regimens and outcomes. The COVID-19 pandemic affected service delivery, delaying HCV diagnosis/treatment and influencing the LTFU rate. Despite challenges, the region maintained high SVR12 rates, emphasizing the importance of sustained efforts in HCV care. Key messages: • The study highlights the dynamic nature of HCV management in Tuscany. • The study emphasises the need for continuous adaptation to public health challenges, providing insights for future public health strategies.
- Open Access
- 5 October 2024
- Published by Springer Nature in BMC Public Health
- Vol. 24 (1) , 1-12
Vaccines and vaccination in prison settings: availability and model of service delivery in 20 European countries
Prisons, due to various risk factors, are environments that are conducive to infectious disease transmission, with significantly higher prevalence of infectious diseases within prisons compared to the general population. This underscores the importance of preventive measures, particularly vaccination. As part of the international project “Reaching the hard-to-reach: Increasing access and vaccine uptake among the prison population in Europe” (RISE-Vac), this study aimed to map the availability and delivery framework of vaccination services in prisons across Europe and beyond. A questionnaire designed to collect data on the availability and delivery model of vaccination services in prisons was validated and uploaded in SurveyMonkey in July 2023. Then, it was submitted to potential participants, with at least one representative from each European country. Potential participants emailed an invitation letter by the RISE-Vac partners and by the European Organization of Prison and Correctional Services (EUROPRIS). Twenty European countries responded. Vaccines are available in European countries, although their availability differs by country and type of vaccine. The first dose is offered to people living in prisons (PLP), mostly within one month, COVID-19 is the most widely offered vaccine. In all countries, vaccines are actively offered by healthcare workers; in most countries, there is no evaluation of vaccination status among people who work in prison. The survey shows variance in vaccine availability for PLP and staff across countries and vaccine types. Quality healthcare in prisons is not only a matter of the right to health but also a critical public health investment: enhancing vaccine uptake consistently among PLP and staff should be prioritized.
- 5 October 2024
- Published by Springer Nature in BMC Public Health
- Vol. 24 (1) , 1-12
Open AccessVaccines and vaccination in prison settings: availability and model of service delivery in 20 European countries
Prisons, due to various risk factors, are environments that are conducive to infectious disease transmission, with significantly higher prevalence of infectious diseases within prisons compared to the general population. This underscores the importance of preventive measures, particularly vaccination. As part of the international project “Reaching the hard-to-reach: Increasing access and vaccine uptake among the prison population in Europe” (RISE-Vac), this study aimed to map the availability and delivery framework of vaccination services in prisons across Europe and beyond. A questionnaire designed to collect data on the availability and delivery model of vaccination services in prisons was validated and uploaded in SurveyMonkey in July 2023. Then, it was submitted to potential participants, with at least one representative from each European country. Potential participants emailed an invitation letter by the RISE-Vac partners and by the European Organization of Prison and Correctional Services (EUROPRIS). Twenty European countries responded. Vaccines are available in European countries, although their availability differs by country and type of vaccine. The first dose is offered to people living in prisons (PLP), mostly within one month, COVID-19 is the most widely offered vaccine. In all countries, vaccines are actively offered by healthcare workers; in most countries, there is no evaluation of vaccination status among people who work in prison. The survey shows variance in vaccine availability for PLP and staff across countries and vaccine types. Quality healthcare in prisons is not only a matter of the right to health but also a critical public health investment: enhancing vaccine uptake consistently among PLP and staff should be prioritized.